Search

Your search keyword '"Herrera-Acosta, Enrique"' showing total 171 results
Start Over Author "Herrera-Acosta, Enrique"
171 results on '"Herrera-Acosta, Enrique"'

2. Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

Author

Daudén, Esteban, de Lima, Glauber Pacelli Gomes, Armesto, Susana, Herrera-Acosta, Enrique, Vidal, David, Villarasa, Eva, Rivera, Raquel, de la Cueva, Pablo, Martorell, Antonio, Ballesca, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero-Maté, Alberto, Pujol-Montcusí, Josep, Salgado, Laura, Sahuquillo-Torralba, Antonio, Coto-Segura, Pablo, Baniandrés, Ofelia, Feltes, Rosa, Alsina, Mercé, and Llamas-Velasco, Mar

Published
2021
Full Text
View/download PDF

3. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

Author

Daudén, Esteban, primary, Escario, Elena, additional, Martos‐Cabrera, Luisa, additional, Armesto, Susana, additional, Herrera‐Acosta, Enrique, additional, Vidal, David, additional, Vilarrasa, Eva, additional, Rivera, Raquel, additional, de la Cueva, Pablo, additional, Martorell, Antonio, additional, Ballesca, Ferran, additional, Belinchón, Isabel, additional, Carretero, Gregorio, additional, Rodríguez, Lourdes, additional, Romero‐Maté, Alberto, additional, Pujol‐Montcusí, J., additional, Salgado, Laura, additional, Sahuquillo‐Torralba, Antonio, additional, Coto‐Segura, Pablo, additional, Baniandrés, Ofelia, additional, Feltes, R., additional, Riera‐Monroig, Josep, additional, Garrido, Jesus, additional, and Llamas‐Velasco, Mar, additional

Published
2024
Full Text
View/download PDF

4. Summer and spring elbow rashes is a variant of polymorphous light eruption: confirmation by photoprovocation and histopathology in a series of five cases

Author

de Gálvez, María Victoria, primary, Castillo-Muñoz, Rosa Maria, additional, López-Navarro, Norberto, additional, López-Jiménez, Patricio, additional, Navarrete-de Gálvez, Enrique, additional, Bosch-García, Ricardo, additional, Herrera-Acosta, Enrique, additional, and Aguilera, José, additional

Published
2023
Full Text
View/download PDF

5. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

Author

Lluch-Galcerá, Juan José, primary, Carrascosa, Jose Manuel, additional, González-Quesada, Alicia, additional, Rivera-Díaz, Raquel, additional, Sahuquillo-Torralba, Antonio, additional, Llamas-Velasco, Mar, additional, Gómez-García, Francisco José, additional, Herrera-Acosta, Enrique, additional, de la Cueva, Pablo, additional, Baniandrés-Rodríguez, Ofelia, additional, Lopez-Estebaranz, Jose Luis, additional, Belinchón, Isabel, additional, Ferrán, Marta, additional, Mateu, Almudena, additional, Rodríguez, Lourdes, additional, Riera-Monroig, Josep, additional, Abalde-Pintos, M Teresa, additional, Carretero, Gregorio, additional, García-Donoso, Carmen, additional, Pujol-Marco, Conrad, additional, Del Alcázar, Elena, additional, Santamaría-Domínguez, Cristina, additional, Suárez-Pérez, Jorge Alonso, additional, Nieto-Benito, Lula María, additional, Ruiz-Genao, Diana Patricia, additional, Salgado-Boquete, Laura, additional, Descalzo, Miguel Ángel, additional, and García-Doval, Ignacio, additional

Published
2023
Full Text
View/download PDF

6. Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice

Author

Ruiz-Villaverde, Ricardo, primary, Herrera-Acosta, Enrique, additional, Ruiz de Casas, Andres, additional, Villegas-Romero, Isabel M., additional, Moreno-Suarez, Fátima G., additional, Vílchez-Márquez, Francisco, additional, Galán-Gutiérrez, Manuel, additional, Vázquez-Bayo, Maria Carmen, additional, Cases-Mérida, Sandra, additional, and Almazán-Fernández, Francisco M., additional

Published
2023
Full Text
View/download PDF

7. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.

Author

Lluch-Galcerá, Juan José, Carrascosa, Jose Manuel, González-Quesada, Alicia, Rivera-Díaz, Raquel, Sahuquillo-Torralba, Antonio, Llamas-Velasco, Mar, Gómez-García, Francisco José, Herrera-Acosta, Enrique, de la Cueva, Pablo, Baniandrés-Rodríguez, Ofelia, Lopez-Estebaranz, Jose Luis, Belinchón, Isabel, Ferrán, Marta, Mateu, Almudena, Rodríguez, Lourdes, Riera-Monroig, Josep, Abalde-Pintos, M Teresa, Carretero, Gregorio, García-Donoso, Carmen, and Pujol-Marco, Conrad

Subjects
BIOTHERAPY, METHOTREXATE, PSORIASIS, POISSON regression, COHORT analysis
Abstract

Background Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis. Objectives The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX. Methods Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class. Results We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57–3.98; P < 0.002). Conclusions The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Author

Chicharro, Pablo, primary, Llamas‐Velasco, Mar, additional, Armesto, Susana, additional, Herrera Acosta, Enrique, additional, Vidal, David, additional, Vilarrasa, Eva, additional, Rivera‐Diaz, Raquel, additional, De‐la‐Cueva, Pablo, additional, Martorell‐Calatayud, Antonio, additional, Ballescà, Ferran, additional, Belinchon, Isabel, additional, Carretero, Gregorio, additional, Rodriguez, Lourdes, additional, Romero‐Maté, Alberto, additional, Pujol‐Montcusí, Josep, additional, Salgado, Laura, additional, Sahuquillo‐Torralba, Antonio, additional, Coto‐Segura, Pablo, additional, Baniandrés Rodríguez, Ofelia, additional, Feltes, Rosa, additional, Riera‐Monroig, José, additional, and Dauden, Esteban, additional

Published
2022
Full Text
View/download PDF

10. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting

Author

Reolid, Alejandra, primary, Armesto, Susana, additional, Sahuquillo-Torralba, Antonio, additional, Torres, Tiago, additional, Feltes, Rosa, additional, Vilarrasa, Eva, additional, Belinchón, Isabel, additional, Cueva, Pablo de la, additional, Rodríguez, Lourdes, additional, Romero-Maté, Alberto, additional, Vidal, David, additional, Coto-Segura, Pablo, additional, Herrera-Acosta, Enrique, additional, Riera-Monroig, Josep, additional, Salgado, Laura, additional, Llamas-Velasco, Mar, additional, and Daudén, Esteban, additional

Published
2022
Full Text
View/download PDF

12. High adherence to secukinumab in patients with moderate to severe psoriasis: a long‐term multicenter study in a daily practice setting

Author

Martos‐Cabrera, Luisa, primary, Llamas‐Velasco, Mar, additional, Armesto, Susana, additional, Herrera‐Acosta, Enrique, additional, Vidal, David, additional, Vilarrasa, Eva, additional, Rivera‐Diaz, Raquel, additional, de la Cueva, Pablo, additional, Martorell‐Calatayud, Antonio, additional, Ballescá, Ferran, additional, Belinchón, Isabel, additional, Carretero, Gregorio, additional, Rodríguez, Lourdes, additional, Romero‐Maté, Alberto, additional, Pujol‐Montcusí, J., additional, Salgado‐Boquete, Laura, additional, Sahuquillo‐Torralba, Antonio, additional, Coto‐Segura, Pablo, additional, Baniandrés, Ofelia, additional, Feltes, R., additional, Alsina, M., additional, and Daudén, Esteban, additional

Published
2022
Full Text
View/download PDF

15. Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis

Author

Herrera-Acosta, Enrique, Garriga-Martina, Gustavo G., Suárez-Pérez, Jorge A., Martínez-García, Eliseo A., and Herrera-Ceballos, Enrique

Subjects
Multiple Sclerosis, Spain, Ixekizumab, Psoriasis, Case Report
Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system that shares similar immunopathogenic mechanisms with chronic plaque psoriasis, such as the overexpression of the Th17 pathway. We report a 50-year-old male patient with MS and severe chronic plaque psoriasis who presented to Hospital Virgen de la Victoria, Málaga, Spain, in 2019. He was successfully treated with ixekizumab (anti-interleukin [IL]-17A and IL-17A/F monoclonal antibody). The treatment achieved complete skin clearance (i.e. a Psoriasis Area Severity Index 100 response) with no adverse event and no evidence of progression of the neurological disease either.

Published
2021

16. Fast and sustained improvement of patient‐reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

Author

Chicharro, Pablo, primary, Llamas‐Velasco, Mar, additional, Armesto, Susana, additional, Herrera‐Acosta, Enrique, additional, Vidal, David, additional, Vilarrasa, Eva, additional, Rivera, Raquel, additional, De la Cueva, Pablo, additional, Martorell‐Calatayud, Antonio, additional, Ballescà, Ferrán, additional, Belinchón, Isabel, additional, Carretero, Gregorio, additional, Rodríguez, Lourdes, additional, Romero‐Maté, Alberto, additional, Pujol‐Montcusí, Josep, additional, Salgado, Laura, additional, Sahuquillo‐Torralba, Antonio, additional, Coto‐Segura, Pablo, additional, Baniandrés‐Rodríguez, Ofelia, additional, Feltes, Rosa, additional, Alsina, Mercè, additional, and Daudén, Esteban, additional

Published
2022
Full Text
View/download PDF

17. High adherence to secukinumab in patients with moderate to severe psoriasis: a long‐term multicenter study in a daily practice setting.

Author

Martos‐Cabrera, Luisa, Llamas‐Velasco, Mar, Armesto, Susana, Herrera‐Acosta, Enrique, Vidal, David, Vilarrasa, Eva, Rivera‐Diaz, Raquel, de la Cueva, Pablo, Martorell‐Calatayud, Antonio, Ballescá, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero‐Maté, Alberto, Pujol‐Montcusí, J., Salgado‐Boquete, Laura, Sahuquillo‐Torralba, Antonio, Coto‐Segura, Pablo, Baniandrés, Ofelia, and Feltes, R.

Subjects
PATIENT compliance, PSORIASIS, PSORIATIC arthritis, PHOTOCHEMOTHERAPY, CLINICAL drug trials
Abstract

A. Sahuquillo-Torralba, Dr. P. Coto-Segura, Dr. O. Baniandrés, Dr. R. Feltes, and Dr. M. Alsina contributed to data collection, discussed the results, and commented on the manuscript. Dr. S. Armesto, Dr. E. Herrera-Acosta, Dr. D. Vidal, Dr. E. Vilarrasa, Dr. R. Rivera, Dr. P. de la Cueva, Dr. I. Belinchón, Dr. G. Carretero, Dr. L. Rodríguez, Dr. [Extracted from the article]

Published
2023
Full Text
View/download PDF

18. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

Author

Daudén, Esteban, Llamas-Velasco, Mar, Santamaría, Cristina, Carretero, Gregorio, Vilar-Alejo, Jaime, Madrid Álvarez, Blanca, Rivera, Raquel, García-Donoso, Carmen, Gomis, Ma del Mar Onteniente, Batista Cabrera, Diana, Ferrándiz, Carlos, Manuel Carrascosa, José, Ballescá, Ferrán, de la Cueva, Pablo, Molina Mejías, Patricia, Belinchón, Isabel, García Giner, Carlos, Perez, Alfred, Gómez-García, Fran J., Herrera-Ceballos, Enrique, Herrera-Acosta, Enrique, Martínez-García, Eliseo, Sánchez, Cristina, López-Estebaranz, José Luis, Patricia Ruiz-Genao, Diana, García Zamora, Elena, Ferrán Farrés, Marta, Alsina, Mercè, Riera, Josep, Pedregosa Fauste, Sara, Baniandrés, Ofelia, María Nieto Benito, Lula, Molina, Desiree, Sánchez-Carazo, José Luis, Sahuquillo-Torralba, Antonio, Botella-Estrada, Rafael, Pujol Marco, Conrad, Chaparro Aguilera, Natalia, Massó López, Verónica, Rodríguez Fernández-Freire, Lourdes, Mateu Puchades, Almudena, Santos, Sergio, Sáez Belló, Marina, Flórez Menéndez, Ángeles, Salgado, Laura, González Sixto, Beatriz, Abalde, Ma Teresa, Vilanova, Lucia, Perez Mariño, Alexandra, Eiris, Noemí, Prieto Marcos, Vicenta, García-Doval, Ignacio, Ángel Descalzo Gallego, Miguel, de Vega Martínez, Marina, Baniandrés-Rodríguez, Ofelia, Carrascosa, José Manuel, Nieto-Benito, Lula María, Fernández-Freire, Lourdes Rodríguez, Ruiz-Genao, Diana Patricia, Riera-Monroig, Josep, and Descalzo Gallego, Miguel Ángel

Published
2021
Full Text
View/download PDF

22. Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry.

Author

Ruiz Genao, Diana P., Carretero, Gregorio, Rivera‐Diaz, Raquel, Carrascosa, Jose Manuel, Sahuquillo‐Torralba, Antonio, Herrera‐Acosta, Enrique, García, Francisco José Gómez, Daudén, Esteban, Estebaranz, Jose Luis López, and Garcia‐Doval, Ignacio

Subjects
PSORIASIS, HEART failure, EPIDEMIOLOGY, PSORIATIC arthritis, COMORBIDITY
Abstract

Regarding therapy, almost all clinical trials exclude patients with pustular psoriasis, limiting the evidence to support therapy for these patients. G.C. has been reimbursed by Janssen, Abbvie, Novartis, Pfizer, MSD and Celgene for advisory service and conferences. There were 3864 patients with PP, 41 patients with generalized pustular psoriasis (GPP) and 294 patients with palmoplantar pustular psoriasis (PPP) included in the study. [Extracted from the article]

Published
2022
Full Text
View/download PDF

23. Aportación de los estudios de práctica clínica real al análisis de la terapia biológica en pacientes con psoriasis moderada-grave

Author

Herrera Acosta, Enrique, Suárez Pérez, Jorge Alonso, Bosch-Garcia, Ricardo Juan, and Medicina y Dermatología

Subjects
Medicina, Dermatología, Psoriasis, Tratamiento, Terapeutica, Piel - Enfermedades - Tesis doctorales, Dermatología - Tesis doctorales
Abstract

La severidad de la enfermedad y la respuesta al tratamiento fue valorada mediante el indicador PASI (Psoriasis Area and Severity Index), realizando mediciones en la visita inicial previa al inicio del tratamiento, así como en las semanas 12, 24 y 52 dependiendo de la serie de tratamiento. Asimismo se recogió la aparición de eventos adversos, el número de pacientes que interrumpieron el tratamiento, el momento y el motivo. Como conclusiones de esta tesis, Los pacientes de práctica clínica real tienen características diferentes a los procedentes de ensayo clínico. Es necesario realizar estudios de práctica clínica real para complementar la información obtenida de los ensayos clínicos. Los pacientes de práctica clínica real han sido refractarios a un número mayor de terapias biológicas previas. En los ensayos clínicos hay una representación menor del sexo femenino respecto a la práctica clínica real. Los datos de respuesta PASI 75, PASI 90 y PASI 100 para secukinumab e ixekizumab, son menores en práctica clínica real respecto a los ensayos clínicos. Ustekinumab, Secukinumab e ixekizumab son fármacos seguros, no habiendo detectado eventos adversos graves durante el seguimiento. Tras el fracaso de un fármaco anti-TNF, es aconsejable el cambio de diana terapéutica. La psoriasis es una enfermedad inmunológicamente mediada, de base genética que afecta a la piel, a las articulaciones o ambas. Debido a su elevada prevalencia, su cronicidad, la afectación psicológica y física que produce y sus comorbilidades, el conocimiento de su patogenia y el manejo del paciente en todas sus dimensiones se ha convertido, hoy día, en un reto para el dermatólogo Los pacientes seleccionados para ensayos clínicos tienen características diferentes a los pacientes de práctica clínica real es por esto que bajo esta premisa nos planteamos esta tesis con el objetivo de: Conocer las diferencias en las características clínicas entre los pacientes procedentes de ensayos clínicos pivotales y los de la unidad de psoriasis del Hospital Universitario Virgen de la Victoria Evaluar la eficacia y seguridad en práctica clínica habitual de secukinumab, ixekizumab y ustekinumab, mediante estudios comparativos no realizados previamente en ensayos clínicos. Comparar la eficacia de secukinumab, ixekizumab y ustekinumab en práctica clínica habitual respecto a los ensayos clínicos publicados. Analizar los motivos de abandono y los acontecimientos adversos de secukinumab, ixekizumab y ustekinumab en práctica clínica habitual respecto a los ensayos clínicos publicados. Todos los pacientes incluidos en este estudio eran adultos con psoriasis en placa crónica, de moderada a grave, tratados con ustekinumab, secukinumab e ixekizumab. Se incluyeron 123 series de tratamiento: 59 series de tratamiento con secukinumab, 35 con ixekizumab y 29 con ustekinumab. Para su comparación, como referencia se utilizaron las series de tratamiento homólogas incluidas en los ensayos pivótales CLEAR e IXORA. Las variables incluidas en el análisis estadístico fueron: edad, sexo, IMC (Índice de Masa Corporal) comorbilidades y tratamientos realizados de forma previa.

Published
2021

24. The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: A cross-sectional study

Author

Moreno-Ramírez, David, Ojeda-Vila, Teresa, Ríos-Martín, Juan J., Ruiz-Villaverde, Ricardo, de-Troya, Magdalena, Sanz-Trelles, Andres, Liébana, Rafael Fúnez, Martínez-de-Victoria, José M., Aneiros-Fernández, Jose, Naranjo-Sintes, Ramón, Amérigo, Joaquín, Alcalde, Mercedes, Zulueta, Teresa, Domínguez-Cruz, Javier J., Solís-García, Eduardo, Tejera-Vaquerizo, Antonio, Martín-Castro, Aurelio M., García-Mellado, Valentín, Martínez-García, Silvestre, Martínez-García, Araceli, Herrera-Acosta, Enrique, Escámez, Pilar Jurado, Rodríguez-Fernández, Antonio M., Salvatierra-Cuenca, Juan, Moreno-Giménez, José C., Guerrero-Cauqui, Rosario, Armario-Hita, Jose C., Nieto-Garcia, Adoración, and Ferrándiz, Lara

Published
2014
Full Text
View/download PDF

26. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

Author

Baniandrés-Rodríguez, Ofelia, primary, Vilar-Alejo, Jaime, additional, Rivera, Raquel, additional, Carrascosa, José Manuel, additional, Daudén, Esteban, additional, Herrera-Acosta, Enrique, additional, Sahuquillo-Torralba, Antonio, additional, Gómez-García, Fran J., additional, Nieto-Benito, Lula María, additional, de la Cueva, Pablo, additional, López-Estebaranz, José Luis, additional, Belinchón, Isabel, additional, Ferrán Farrés, Marta, additional, Alsina, Mercè, additional, Fernández-Freire, Lourdes Rodríguez, additional, Carretero, Gregorio, additional, García-Donoso, Carmen, additional, Ballescá, Ferrán, additional, Llamas-Velasco, Mar, additional, Herrera-Ceballos, Enrique, additional, Botella-Estrada, Rafael, additional, Ruiz-Genao, Diana Patricia, additional, Riera-Monroig, Josep, additional, Descalzo Gallego, Miguel Ángel, additional, García-Doval, Ignacio, additional, Santamaría, Cristina, additional, Madrid Álvarez, Blanca, additional, Gomis, Ma del Mar Onteniente, additional, Batista Cabrera, Diana, additional, Ferrándiz, Carlos, additional, Manuel Carrascosa, José, additional, Molina Mejías, Patricia, additional, García Giner, Carlos, additional, Perez, Alfred, additional, Martínez-García, Eliseo, additional, Sánchez, Cristina, additional, Patricia Ruiz-Genao, Diana, additional, García Zamora, Elena, additional, Riera, Josep, additional, Pedregosa Fauste, Sara, additional, Baniandrés, Ofelia, additional, María Nieto Benito, Lula, additional, Molina, Desiree, additional, Sánchez-Carazo, José Luis, additional, Pujol Marco, Conrad, additional, Chaparro Aguilera, Natalia, additional, Massó López, Verónica, additional, Rodríguez Fernández-Freire, Lourdes, additional, Mateu Puchades, Almudena, additional, Santos, Sergio, additional, Sáez Belló, Marina, additional, Flórez Menéndez, Ángeles, additional, Salgado, Laura, additional, González Sixto, Beatriz, additional, Abalde, Ma Teresa, additional, Vilanova, Lucia, additional, Perez Mariño, Alexandra, additional, Eiris, Noemí, additional, Prieto Marcos, Vicenta, additional, Ángel Descalzo Gallego, Miguel, additional, and de Vega Martínez, Marina, additional

Published
2021
Full Text
View/download PDF

31. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.

Author

Munera-Campos, Mónica, Vilar-Alejo, Jaime, Rivera, Raquel, Carrascosa, Jose-Manuel, Daudén, Esteban, Herrera-Acosta, Enrique, Sahuquillo-Torralba, Antonio, Gómez-García, Francisco J., Baniandrés-Rodríguez, Ofelia, de la Cueva, Pablo, López-Estebaranz, Jose-Luis, Belinchón, Isabel, Ferran, Marta, Riera-Monroig, Jose, Rodriguez, Lourdes, Carretero, Gregorio, García-Donoso, Carmen, Ballescá, Ferran, Llamas-Velasco, Mar, and Herrera-Ceballos, Enrique

Subjects
FATTY liver, NON-alcoholic fatty liver disease, PSORIASIS, COHORT analysis, LONGITUDINAL method
Abstract

Limited information is available regarding the risk of incident liver disease in patients with psoriasis receiving systemic therapies. To describe the liver safety findings of conventional and modern systemic therapies for moderate-to-severe psoriasis, and to compare the relative incidence rates of hepatic adverse events (AEs) for each drug. All the patients on the BIOBADADERM registry were included. Crude and adjusted incidence rate ratios (cIRR and aIRR, respectively) of hepatic AEs, using anti-TNF drugs as reference, were determined. Outcomes of interest were hypertransaminasemia, nonalcoholic fatty liver disease (NADFLD) and a group of other, less represented, hepatic AEs. Our study included 3,171 patients exposed to systemic drugs (6279 treatment cycles). Incident hypertransaminasemia was the most frequent hepatic AE (incidence rate of 21 per 1000 patients-years [CI 95% 18–23]), followed by NAFLD (8 cases per 1000 patients-years [95% CI 6–10]). Methotrexate (aIRR 3.06 [2.31–4.4]; p = 0.000) and cyclosporine (aIRR 2.37 [1.05–5.35]; p =.0378) were associated with an increased risk for hypertransaminasemia when compared to anti-TNF-α agents. No differences were observed between different groups of biologics. Conventional therapies were not associated with new incident NAFLD. Comparative information of the incidence of hepatic AEs could facilitate drug selection in moderate-to-severe psoriasis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

Author

Daudén, Esteban, primary, Carretero, Gregorio, additional, Rivera, Raquel, additional, Ferrándiz, Carlos, additional, Llamas-Velasco, Mar, additional, de la Cueva, Pablo, additional, Belinchón, Isabel, additional, Gómez-García, Francisco José, additional, Herrera-Acosta, Enrique, additional, Ruiz-Genao, Diana Patricia, additional, Ferrán-Farrés, Marta, additional, Alsina, Mercè, additional, Baniandrés-Rodríguez, Ofelia, additional, Sánchez-Carazo, José Luis, additional, Sahuquillo-Torralba, Antonio, additional, Fernández-Freire, Lourdes Rodriguez, additional, Vilar-Alejo, Jaime, additional, García-Donoso, Carmen, additional, Carrascosa, José Manuel, additional, Herrera-Ceballos, Enrique, additional, López-Estebaranz, José Luis, additional, Botella-Estrada, Rafael, additional, Segovia-Muñoz, Eva, additional, Descalzo, Miguel Angel, additional, García-Doval, Ignacio, additional, Daudén, Esteban, additional, Ballescá, Ferrán, additional, Cueva, Pablo de la, additional, Gómez-García, Fran J., additional, Jiménez, Rafael, additional, Farrés, Marta Ferrán, additional, Baniandrés, Ofelia, additional, Nieto, Lula, additional, Marco, Conrad Pujol, additional, Fernández-Freire, Lourdes Rodríguez, additional, Puchades, Almudena Mateu, additional, Menéndez, Ángeles Flórez, additional, Salgado, Laura, additional, Sixto, Beatriz González, additional, Eiris, Noemí, additional, Descalzo Gallego, Miguel Ángel, additional, and de Vega Martínez, Marina, additional

Published
2020
Full Text
View/download PDF

39. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

Author

Sahuquillo-Torralba, Antonio, primary, Carretero, Gregorio, additional, Rivera, Raquel, additional, Ferrándiz, Carlos, additional, Daudén-Tello, Esteban, additional, de la Cueva, Pablo, additional, Gómez-García, Francisco José, additional, Belinchón, Isabel, additional, Herrera-Acosta, Enrique, additional, Ruiz-Genao, Diana, additional, Ferrán, Marta, additional, Alsina, Mercé, additional, Sánchez-Carazo, Jose Luís, additional, Baniandrés, Ofelia, additional, Fernández-Freire, Lourdes Rodríguez, additional, Vilar, Jaime, additional, García-Donoso, Carmen, additional, Carrascosa, Jose Manuel, additional, Llamas-Velasco, Mar, additional, Herrera-Ceballos, Enrique, additional, López-Estebaranz, José Luis, additional, Pujol-Marco, Conrad, additional, Descalzo, Miguel Ángel, additional, and García-Doval, Ignacio, additional

Published
2020
Full Text
View/download PDF

48. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.

Author

HERNÁNDEZ-FERNÁNDEZ, Carlos Pelayo, CARRETERO, Gregorio, RIVERA, Raquel, FERRÁNDIZ, Carlos, DAUDÉN, Esteban, DE LA CUEVA, Pablo, BELINCHÓN, Isabel, GÓMEZ-GARCÍA, Francisco Javier, HERRERA-ACOSTA, Enrique, RUIZ-GENAO, Diana P., FERRÁN, MARTA, ALSINA, Mercé, BANIANDRÉS-RODRÍGUEZ, Ofelia, SÁNCHEZ-CARAZO, Jose Luis, BOTELLA-ESTRADA, Rafael, SAHUQUILLO-TORRALBA, Antonio, RODRIGUEZ, Lourdes, VILAR-ALEJO, Jaime, GARCÍA-DONOSO, Carmen, and CARRASCOSA, Jose M.

Subjects
PSORIASIS treatment, GENDER, PSORIASIS, TREATMENT effectiveness, DRUG prescribing
Abstract

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

Author

Descalzo, Miguel Angel, Carretero, Gregorio, Ferrándiz, Carlos, Rivera, Raquel, Daudén, Esteban, Gómez-García, Fran J, de la Cueva, Pablo, Herrera-Ceballos, Enrique, Belinchón, Isabel, López-Estebaranz, José Luis, Alsina, Mercè, Sánchez-Carazo, José Luis, Ferrán, Marta, Baniandrés, Ofelia, Carrascosa, José Manuel, Llamas-Velasco, Mar, Ruiz-Genao, Diana, Herrera-Acosta, Enrique, Muñoz-Santos, Carlos, García-Doval, Ignacio, and Biobadaderm Study Group

Subjects
0301 basic medicine, Change over time, Male, medicine.medical_specialty, Time Factors, Drug-Related Side Effects and Adverse Reactions, Dermatology, Systemic therapy, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Psoriasis, medicine, Humans, In patient, Adverse effect, Time trends, business.industry, Diagnostic test, Middle Aged, medicine.disease, Surgery, 030104 developmental biology, Female, business, Psoriasi -- Tractament, Cohort study
Published
2017

50. Quality of Life of Cohabitants of People Living with Acne.

Author

MARTÍNEZ-GARCÍA, Eliseo, ARIAS-SANTIAGO, Salvador, HERRERA-ACOSTA, Enrique, AFFLECK, Andrew, HERRERACEBALLOS, Enrique, and BUENDÍA-EISMAN, Agustín

Subjects
QUALITY of life, ACNE, PSYCHOLOGICAL well-being
Abstract

The aim of this study was to analyse the levels of anxiety, depression, and quality of life of individuals living with acne patients (cohabitants). The study included patients, cohabitants, and controls; a total of 204 participants. Patients' health-related quality of life was measured with the Dermatology Life Quality Index (DLQI), while cohabitants' quality of life was measured with the Family Dermatology Life Quality Index (FDLQI). The psychological state of all participants was measured with the Hospital Anxiety and Depression Scale (HADS). Presence of acne impaired the quality of life of 89.4% of the cohabitants. The FDLQI scores of cohabitants were significantly associated with the DLQI scores of the patients (rp = 0.294; p = 0.044). Anxiety and depression levels in cohabitants were significantly higher than in controls (p < 0.01). In conclusion, acne may have a negative impact on quality of life and psychological well-being of patients and their cohabitants. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results